China OKs Clinical Testing of First CAR T-cell Therapy in NMOSD
Authorities in China have granted IASO Biotherapeutics the go-ahead to begin clinical testing of the experimental CAR T-cell therapy equecabtagene autoleucel in people with neuromyelitis optica spectrum disorder (NMOSD), IASO announced. NMOSD is an autoimmune disorder wherein the body’s immune system launches an inflammatory attack that damages parts…